All Updates

ALBANY, NY – APRIL 12, 2023 – Earlier today, JUUL announced it will pay $462 million to settle a multi-state investigation into its underage marketing practices to attract young consumers to its addictive e-cigarettes. This settlement is evidence that JUUL intentionally preyed upon young consumers with the sole goal of

Attorneys General for six states and DC today announced a $462 million multi-state settlement to be paid out by JUUL Labs, following an investigation into its underage marketing practices to attract youth to its addictive e-cigarettes.

Attorneys General for six states and DC today announced a $462 million multi-state settlement to be paid out by JUUL Labs, following an investigation into its underage marketing practices to attract youth to its addictive e-cigarettes.

JUUL announced it will pay $462 million to settle a multi-state investigation into its underage marketing practices to attract young consumers to its addictive e-cigarettes. Under the settlement, California will receive $175.8 million.

JUUL announced it will pay $462 million to settle a multi-state investigation into its underage marketing practices to attract young consumers to its addictive e-cigarettes. Under the settlement, California will receive $175.8 million.

Our organizations, representing patients with serious health conditions, condemn Judge Kacsmaryk’s decision which threatens to restrict access to a Food and Drug Administration (FDA)- approved medication and other treatments.

ACS CAN volunteers from across California rallied at the State Capitol and urged lawmakers to pass legislation that would ensure comprehensive biomarker testing is covered by more insurance plans, including Medi-Cal, when supported by medical and scientific evidence.

ACS CAN volunteers from across California rallied at the State Capitol and urged lawmakers to pass legislation that would ensure comprehensive biomarker testing is covered by more insurance plans, including Medi-Cal, when supported by medical and scientific evidence.

Our organizations, representing patients with serious health conditions, condemn Judge Kacsmaryk’s decision which threatens to restrict access to a Food and Drug Administration (FDA)- approved medication and other treatments.